Combining mepacrine with hydroxychloroquine-based therapy in active systemic lupus erythematosus: an observational study of 106 patients from the Lupus-Cruces cohort
Beatriz Marín-García, Luis Dueña-Bartolomé, Oihane Montero, Guillermo Ruiz-Irastorza · 2025
Read Combining mepacrine with hydroxychloroquine-based therapy in active systemic lupus erythematosus: an observational study of 106 patients from the Lupus-Cruces cohort by Beatriz Marín-García, Luis Dueña-Bartolomé, Oihane Montero, Guillermo Ruiz-Irastorza (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12730743.txt.
Description
Beatriz Marín-García and co-authors test an add-on drug for active lupus in a 2025 study of 106 cases from a Spanish cohort. All patients took hydroxychloroquine plus prednisone, yet their disease stayed active. The team added mepacrine and checked who reached remission after six months.
Remission by the strict DORIS standard came for 71 percent of the whole group. Those on simple therapy hit 79 percent, against 62 percent for those also on stronger immune drugs. Disease activity scores fell by about the same amount in both groups. Steroid doses also tapered alike. The most common reason for stopping the add-on was lack of effect or side effects. The results support mepacrine as a useful extra step when base therapy falls short.
Catalog record
| CREATOR | Beatriz Marín-García, Luis Dueña-Bartolomé, Oihane Montero, Guillermo Ruiz-Irastorza |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |